{
    "clinical_study": {
        "@rank": "70505", 
        "acronym": "PEG-rhG-CSF", 
        "arm_group": [
            {
                "arm_group_label": "pegfilgrastim,30mcg/kg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "pegfilgrastim, 60mcg/kg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "pegfilgrastim,100mcg/kg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "filgrastim,5mcg/kg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a\n      single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia."
        }, 
        "brief_title": "Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia", 
        "condition": "Neutropenia", 
        "condition_browse": {
            "mesh_term": "Neutropenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age:18-70 years\uff1b\n\n          -  Comfirmed advanced tumor patients by histopathological with regarding\n             initialtreatment or adjuvant, or neoadjuvant chemotherapy,suitable for chemotherapy\n             with canboplatin combined with taxol or cyclophosphamide combined with pharmorubicin\n             in the opinion of the investigator\uff1b\n\n          -  Performance status\uff08EOCG\uff09\u22641\uff1b\n\n          -  Normal human peripheral blood are eligible for the chemotherapy, WBC\u22653,500 per cubic\n             millilit, ANC \u2265 1,500 per cubic milliliter, PLT \u2265 100,000 per cubic milliliter\uff1b\n\n          -  Normal ECG examination\uff1b\n\n          -  Without liver metastasis patients: the level of ALT\u3001TBIL\u3001AST were in the 2.5 times of\n             upper normal limit; Liver metastasis patients: the level of ALT\u3001TBIL\u3001AST were in the\n             5 times of upper normal limit;\n\n          -  Renal function indices\uff1athe level of Cr\u3001BUN were bothe in the 1.25 times of upper\n             normal limit;\n\n          -  Life expectancy \uff1e3 months;\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Be treated with radiotherapy in nearly 4 weeks(not included local radiotherapy for\n             the bone metastasis);\n\n          -  Be treated with hemopoietic stem cell transplantation or bone marrow transplant\uff1b\n\n          -  Not adequately controlled infections(e.g. ANC \u2265 12,000 per cubic\n             milliliter,temperature > 38.2\u2103)\n\n          -  Evidence of metastatic disease in bone marrow,or with other malignant tumors \uff08not\n             included cured basal cell carcinoma and endometrial carcinoma\uff09\uff1b\n\n          -  Subjects with unconscious or symptomatic brain metastases\uff1b\n\n          -  Subjects with serious heart\u3001liver and renal disease;\n\n          -  Subjects with serious diabetes or poor control in glycemia;\n\n          -  Pregnant or breast-feeding period females;\n\n          -  Be treated with  antibiotics in 72 hours or currently being treated with antibiotics;\n\n          -  Treated with PEG-rhG-CSF in past;\n\n          -  Participated 3 or more than 3 clinical trials in nearly a year(as subjects) or any\n             clinical trials in nearly 3 months;\n\n          -  Allergic disorders or allergies subjects or known hypersensitivity to filgrastim or\n             any of the products to be administered during dosing;\n\n          -  Suspected or comfirmed evidences of drug\u3001treatment of drugs or alcohol abused;\n\n          -  Serious Neurological disorders that would affect the consent or observation;\n\n          -  Other conditions which in the opinion of the investigator preclude enrollment into\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918241", 
            "org_study_id": "JY062013B"
        }, 
        "intervention": [
            {
                "arm_group_label": "pegfilgrastim,30mcg/kg", 
                "description": "Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.", 
                "intervention_name": "pegfilgrastim,30mcg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pegfilgrastim, 60mcg/kg", 
                "description": "Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.", 
                "intervention_name": "pegfilgrastim, 60mcg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pegfilgrastim,100mcg/kg", 
                "description": "Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.", 
                "intervention_name": "pegfilgrastim, 100mcg/kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "filgrastim,5mcg/kg", 
                "description": "At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.", 
                "intervention_name": "filgrastim, 5mcg/kg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pegylation", 
            "G-CSF", 
            "Efficacy", 
            "Satety"
        ], 
        "lastchanged_date": "August 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute and Hospital, CAMS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia", 
        "overall_contact": {
            "last_name": "Yan Qin, M.D.", 
            "phone": "010-8778-8507"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Duration of \u2265grade 3 neutropenia in cycle 2", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918241"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence of \u2265grade 3 neutropenia;\nIncidence of febrile neutropenia;\nMeasurement the duration from chemotherapy finished to the ANC reached the nadir and the value of ANC`s nadir;\nTime to ANC recovery,the time from chemotherapy administration  until the patient`s ANC increasd to 2.0*109/L after the expected nadir", 
            "measure": "change of Neutropenia and ANC in cycle 2", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "source": "Hangzhou Jiuyuan Gene Engineering Co. Ltd.,", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Institute and Hospital, CAMS", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beijing Cancer Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hebei Tumor Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "LIN YI TUMOUR HOSPITAL", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital, School of Medicine, Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jiangsu Cancer Institute & Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jiangsu Province Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wuhan Union Hospital, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wuhan TongJi Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wuhan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hunan Province Tumor Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Affiliated Hospital of Inner Mongolia Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Cancer Hospital and Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hangzhou Jiuyuan Gene Engineering Co. Ltd.,", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}